3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Authors

Institutions

Publication Details

Published
2024-08-01
DOI
https://doi.org/10.1136/bmjno-2024-anzan.120
Citations
1
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Charles Benjamin Malpas, Sifat Sharmin, Jeannette Lechner‐Scott, Nevin John et al.
1 citations
Chronic Lymphocytic Leukemia Research
0.44
article

3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Charles Benjamin Malpas, Sifat Sharmin, Jeannette Lechner‐Scott, Nevin John, Tomáš Kalinčík, Katherine Buzzard, Helmut Butzkueven, Anneke van der Walt, Izanne Roos, Suzanne Hodgkinson, Michael Harry Barnett, Olga Skibina
article en
1 citations

Abstract

No abstract available for this paper.
The Royal Melbourne Hospital (AU), Box Hill Hospital (AU), The University of Melbourne (AU), John Hunter Hospital (AU), The Alfred Hospital (AU), Eastern Health (AU), Mind Australia (AU), Ingham Institute (AU), Hunter New England Local Health District (AU), Monash University (AU)
Zero hunger
Openalex Percentile: Top 34%
Chronic Lymphocytic Leukemia Research
0.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.